Cost-effective, evidence-based infertility care

Economic evaluation of health care interventions is becoming increasingly important as the demand for services increases. For unexplained infertility, in-vitro fertilization is not a cost-effective first-line treatment option compared with ovarian stimulation and intrauterine insemination. In clomiphene citrate-resistant polycystic ovarian syndrome, in-vitro fertilization may be cost-effective.